Patents by Inventor Owen Brendan Wallace

Owen Brendan Wallace has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS
    Publication number: 20240139163
    Abstract: The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula I: or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.
    Type: Application
    Filed: December 20, 2022
    Publication date: May 2, 2024
    Inventors: Ivan Viktorovich Efremov, Steven Kazmirski, Qingyi Li, Lorin A. Thompson, III, Owen Brendan Wallace, Shawn Donald Johnstone, Feng Zhou, Peter Rahl
  • USE OF P38 INHIBITORS TO REDUCE EXPRESSION OF DUX4
    Publication number: 20230257743
    Abstract: The present invention relates to compositions and methods of inhibiting p38 kinase to reduce gene and protein expression of DUX4 and downstream genes regulated by DUX4. The present invention further relates to methods for treating patients suffering from diseases associated with increased expression of DUX4 or expression of an aberrant form of DUX4, such as Facioscapulohumeral muscular dystrophy (FSHD).
    Type: Application
    Filed: September 20, 2022
    Publication date: August 17, 2023
    Inventors: Angela Marie Cacace, Luis Gustavo Alejandro Rojas Soto, Lorin A. Thompson, III, Owen Brendan Wallace, Lucienne V. Ronco, Ning Shen, Alan Scott Robertson, Aaron Nakwon Chang
  • Macrocyclic azolopyridine derivatives as EED and PRC2 modulators
    Patent number: 11590111
    Abstract: The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula I: or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: February 28, 2023
    Assignee: Fulcrum Therapeutics, Inc.
    Inventors: Ivan Viktorovich Efremov, Steven Kazmirski, Qingyi Li, Lorin A. Thompson, III, Owen Brendan Wallace, Shawn Donald Johnstone, Feng Zhou, Peter Rahl
  • Use of p38 inhibitors to reduce expression of DUX4
    Patent number: 11479770
    Abstract: The present invention relates to compositions and methods of inhibiting p38 kinase to reduce gene and protein expression of DUX4 and downstream genes regulated by DUX4. The present invention further relates to methods for treating patients suffering from diseases associated with increased expression of DUX4 or expression of an aberrant form of DUX4, such as Facioscapulohumeral muscular dystrophy (FSHD).
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: October 25, 2022
    Assignee: Fulcrum Therapeutics, Inc.
    Inventors: Angela Marie Cacace, Luis Gustavo Alejandro Rojas Soto, Lorin A. Thompson, III, Owen Brendan Wallace, Lucienne V. Ronco, Ning Shen, Alan Scott Robertson, Aaron Nakwon Chang
  • P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD
    Publication number: 20220282254
    Abstract: The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A. Methods useful for treating a disease associated with abnormal DUX4 and downstream gene expression (e.g., Fascioscapulohumeral muscular dystrophy) are disclosed.
    Type: Application
    Filed: May 11, 2022
    Publication date: September 8, 2022
    Inventors: Angela Marie Cacace, Luis Gustavo Alejandro Rojas Soto, Lorin A. Thompson, Iii, Owen Brendan Wallace, Lucienne V. Ronco, Ning Shen, Alan Scott Robertson, Aaron Nakwon Chang
  • MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS
    Publication number: 20220160686
    Abstract: The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula I: or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.
    Type: Application
    Filed: February 18, 2021
    Publication date: May 26, 2022
    Inventors: Ivan Viktorovich Efremov, Steven Kazmirski, Qingyi Li, Lorin A. Thompson, III, Owen Brendan Wallace, Shawn Donald Johnstone, Feng Zhou, Peter Rahl
  • P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD
    Publication number: 20220133704
    Abstract: The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A. Methods useful for treating a disease associated with abnormal DUX4 and downstream gene expression (e.g., Fascioscapulohumeral muscular dystrophy) are disclosed.
    Type: Application
    Filed: November 12, 2021
    Publication date: May 5, 2022
    Inventors: Angela Marie Cacace, Luis Gustavo Alejandro Rojas Soto, Lorin A. Thompson, III, Owen Brendan Wallace, Lucienne V. Ronco, Ning Shen, Alan Scott Robertson, Aaron Nakwon Chang
  • P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
    Patent number: 11291659
    Abstract: The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A. Methods useful for treating a disease associated with abnormal DUX4 and downstream gene expression (e.g., Fascioscapulohumeral muscular dystrophy) are disclosed.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: April 5, 2022
    Assignee: Fulcrum Therapeutics, Inc.
    Inventors: Angela Marie Cacace, Luis Gustavo Alejandro Rojas Soto, Lorin A. Thompson, III, Owen Brendan Wallace, Lucienne V. Ronco, Ning Shen, Alan Scott Robertson, Aaron Nakwon Chang
  • Macrocyclic azolopyridine derivatives as EED and PRC2 modulators
    Patent number: 10973805
    Abstract: The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula I: or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: April 13, 2021
    Assignee: Fulcrum Therapeutics, Inc.
    Inventors: Ivan Viktorovich Efremov, Steven Kazmirski, Qingyi Li, Lorin A. Thompson, III, Owen Brendan Wallace, Shawn Donald Johnstone, Feng Zhou, Peter Rahl
  • P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD
    Publication number: 20200383963
    Abstract: The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, orZNF280A. Methods useful for treating a disease associated with abnormal DUX4 and downstream gene expression (e.g., Fascioscapulohumeral muscular dystrophy) are disclosed.
    Type: Application
    Filed: January 21, 2020
    Publication date: December 10, 2020
    Inventors: Angela Marie CACACE, Luis Gustavo Alejandro ROJAS SOTO, Lorin A. THOMPSON, III, Owen Brendan WALLACE, Lucienne V. RONCO, Ning SHEN, Alan Scott ROBERTSON, Aaron Nakwon CHANG
  • MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS
    Publication number: 20200360353
    Abstract: The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula I or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.
    Type: Application
    Filed: April 24, 2020
    Publication date: November 19, 2020
    Inventors: Ivan Viktorovich EFREMOV, Steven KAZMIRSKI, Qingyi LI, Lorin A. THOMPSON, III, Owen Brendan WALLACE, Shawn Donald JOHNSTONE, Feng ZHOU, Peter RAHL
  • USE OF P38 INHIBITORS TO REDUCE EXPRESSION OF DUX4
    Publication number: 20200332291
    Abstract: The present invention relates to compositions and methods of inhibiting p38 kinase to reduce gene and protein expression of DUX4 and downstream genes regulated by DUX4. The present invention further relates to methods for treating patients suffering from diseases associated with increased expression of DUX4 or expression of an aberrant form of DUX4, such as Facioscapulohumeral muscular dystrophy (FSHD).
    Type: Application
    Filed: October 5, 2018
    Publication date: October 22, 2020
    Inventors: Angela Marie CACACE, Luis Gustavo Alejandro ROJAS SOTO, Lorin A. THOMPSON, III, Owen Brendan WALLACE, Lucienne V. RONCO, Ning SHEN, Alan Scott ROBERTSON, Aaron Nakwon CHANG
  • P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
    Patent number: 10537560
    Abstract: The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A. Methods useful for treating a disease associated with abnormal DUX4 and downstream gene expression (e.g., Fascioscapulohumeral muscular dystrophy) are disclosed.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: January 21, 2020
    Assignee: Fulcrum Therapeutics. Inc.
    Inventors: Angela Marie Cacace, Luis Gustavo Alejandro Rojas Soto, Lorin A. Thompson, III, Owen Brendan Wallace, Lucienne V. Ronco, Ning Shen, Alan Scott Robertson, Aaron Nakwon Chang
  • P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
    Patent number: 10342786
    Abstract: The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A. Methods useful for treating a disease associated with abnormal DUX4 and downstream gene expression (e.g., Fascioscapulohumeral muscular dystrophy) are disclosed.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: July 9, 2019
    Assignee: Fulcrum Therapeutics, Inc.
    Inventors: Angela Marie Cacace, Luis Gustavo Alejandro Rojas Soto, Lorin A. Thompson, III, Owen Brendan Wallace, Lucienne V. Ronco, Ning Shen, Alan Scott Robertson, Aaron Nakwon Chang
  • P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD
    Publication number: 20190105311
    Abstract: The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A. Methods useful for treating a disease associated with abnormal DUX4 and downstream gene expression (e.g., Facioscapulohumeral muscular dystrophy) are disclosed.
    Type: Application
    Filed: October 19, 2018
    Publication date: April 11, 2019
    Inventors: Angela Marie CACACE, Luis Gustavo Alejandro ROJAS SOTO, Lorin A. THOMPSON, III, Owen Brendan WALLACE
  • P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD
    Publication number: 20190105312
    Abstract: The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A. Methods useful for treating a disease associated with abnormal DUX4 and downstream gene expression (e.g., Fascioscapulohumeral muscular dystrophy) are disclosed.
    Type: Application
    Filed: November 19, 2018
    Publication date: April 11, 2019
    Inventors: Angela Marie CACACE, Luis Gustavo Alejandro ROJAS SOTO, Lorin A. THOMPSON, III, Owen Brendan WALLACE
  • Selective estrogen receptor modulators for the treatment of vasomotor symptoms
    Patent number: 8217032
    Abstract: The present invention relates to a selective estrogen receptor modulator of formula I or Ia: (I) (Ia); or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms, in particular hot flashes, night sweats and other symptoms that affect women around menopause.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: July 10, 2012
    Assignee: Eli Lilly and Company
    Inventors: Robert Dean Dally, Jeffrey Alan Dodge, Scott Alan Frank, Ronald Jay Hinklin, Timothy Alan Shepherd, Owen Brendan Wallace
  • Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
    Patent number: 8153807
    Abstract: The present invention discloses novel compounds of Formula I: (I) having 11-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11-HSD type 1 activity.
    Type: Grant
    Filed: April 23, 2007
    Date of Patent: April 10, 2012
    Assignee: Eli Lilly and Company
    Inventors: Julie Kay Bush, Marvin Martin Hansen, Renhua Li, Thomas Edward Mabry, Nancy June Snyder, Owen Brendan Wallace, Yanping Xu
  • Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
    Patent number: 8148534
    Abstract: The present invention discloses novel compounds of Formula I: (I) possessing 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11?-HSD type 1 activity.
    Type: Grant
    Filed: April 25, 2007
    Date of Patent: April 3, 2012
    Assignee: Eli Lilly and Company
    Inventors: Renhua Li, Owen Brendan Wallace, Yanping Xu
  • Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
    Patent number: 8088776
    Abstract: The present invention discloses novel compounds of Formula I: possessing 11 ?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 ?-HSD type 1 activity.
    Type: Grant
    Filed: April 19, 2007
    Date of Patent: January 3, 2012
    Assignee: Eli Lilly and Company
    Inventors: Thomas Daniel Aicher, Zhaogen Chen, Ronald Jay Hinklin, Gary Alan Hite, Alexei Pavlovych Krasutsky, Renhua Li, Jefferson Ray McCowan, Ashraf Saeed, Nancy June Snyder, James Lee Toth, Owen Brendan Wallace, Leonard Larry Winneroski, Jr., Yanping Xu, Jeremy Schulenburg York